FDA
-
-
-
-
-
-
-
AC Immune SA (ACIU) Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
-
-
-
-
-
-
-
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
-
-
-
-
-
-
-
Roche Alzheimer's drug fails, joining long list of trial flops
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

